R-Pharm Overseas, Inc. (San Diego, CA), a division of R-Pharm Group, signed an exclusive licensing agreement with Aspyrian Therapeutics Inc. (San Diego, CA). Aspyrian acquired global rights to use an antibody owned by R-Pharm for its further development based on a technology platform Photoimmunotherapy, and commercialization of medicines for treatment of oncological diseases.
“We are pleased to conclude a licensing agreement with R-Pharm Group, which gives us access to the antibody that we are planning to use as a basis to develop our own products. R-Pharm Group is a new, rising leader in the development of biotechnology, and we expect to obtain the synergy effect from using R-Pharm products,” said Miguel Garcia-Guzman, President and CEO of Aspyrian Therapeutics, Inc.
“The antibody was developed by R-Pharm with the support of the Russian Ministry of Industry and Trade under the federal target-oriented program for the development of pharmaceutical and medical industry (Pharma-2020). We will be glad to continue working together with Aspyrian on creation of new medicines for treatment of such life-threatening disease as cancer,” said Vasily Ignatyev, CEO of R-Pharm Group.